gdc
Side-Effects Management

Drugs for Side-Effects Management (Supportive Care)

Here are the financial support services available to patients receiving treatment for Side-Effects Management (Supportive Care).
Anemia

Aranesp (darbepoetin alfa)

Drug company: Amgen
888-427-7478

Aranesp is an erythropoiesis-stimulating drug used for the treatment of patients with anemia associated with myelosuppressive chemotherapy.

Amgen offers 1 financial assistance program for patients using Aranesp:

Amgen Safety Net Foundation

Patients with limited or no drug coverage, and patients with Medicare Part D who satisfy the income eligibility requirements, can receive Aranesp for free through this nonprofit program from Amgen.

Epogen (epoetin alfa)

Drug company: Amgen
888-427-7478

Epogen is an erythropoiesis-stimulating drug used for the treatment of patients with anemia associated with myelosuppressive chemotherapy.

(Amgen currently does not offer any financial assistance programs for Epogen.)

Injectafer (ferric carboxymaltose injection)

Drug company: Daiichi-Sankyo
866-741-7276

Injectafer is an iron replacement drug used for the treatment of adult patients with anemia associated with iron deficiency in patients with cancer.

American Regent offers 2 financial assistance programs for patients using Injectafer:

Injectafer Savings Program

Through this program, qualifying patients with private insurance will pay the first $50 for the first dose of Injectafer and then pay as little as $0 for the second dose. Patients can receive up to $500 in assistance for each dose of Injectafer, with a maximum benefit of $1,000 for every 2 doses.

Injectafer Patient Assistance Program

Patients who are uninsured and are not eligible for public (government) assistance may qualify to receive Injectafer for free if they meet certain income criteria.

Retacrit (epoetin alfa-epbx)

Drug company: Pfizer
844-722-6672

Retacrit, a biosimilar to Epogen and Procrit, is an erythropoiesis-stimulating agent used for the treatment of anemia associated with concomitant myelosuppressive chemotherapy in patients with non-myeloid cancer who need at least 2 additional months of chemotherapy.

Pfizer enCompass offers 1 financial assistance program for patients who have been prescribed Retacrit:

Pfizer Patient Assistance Program

Through this program, patients who are underinsured or uninsured may qualify to receive Retacrit for free or at a savings. Eligible patients who have government insurance may also be able to receive Retacrit for free if they cannot find support from an independent charitable foundation.

Bone Metastases/Reduced Bone Mass

Prolia (denosumab) Injection

Drug company: Amgen
888-427-7478

Prolia is a RANK ligand inhibitor used to increase bone mass in adults at high risk for fracture, specifically men who receive androgen-deprivation therapy for nonmetastatic prostate cancer and women who receive adjuvant aromatase inhibitor therapy for breast cancer.

Amgen has 3 financial assistance programs available for patients using Prolia:

Prolia Copay Program

Through this program, eligible patients with private insurance will pay $25 or less out-of-pocket for each dose of Prolia, with an annual benefit of up to $1,500.

Prolia FIRST STEP Program

For privately insured patients whose insurance covers Prolia, this program provides a copay of $0 for the first dose and $25 for each dose thereafter, with a maximum benefit of $1,500 per patient per calendar year.

Amgen Safety Net Foundation

Patients with limited or no drug coverage, and patients with Medicare Part D who satisfy the income eligibility requirements, can receive Prolia for free through this nonprofit program from Amgen.

Xgeva (denosumab)

Drug company: Amgen
888-427-7478

Xgeva is a RANK ligand inhibitor used for the prevention of skeletal-related events in patients with bone metastases from solid tumors, as well as for the treatment of patients with giant-cell tumor of the bone.

Amgen offers 2 financial assistance programs for patients using Xgeva:

Xgeva First Step

For privately insured patients whose insurance covers Xgeva, this program ensures a copay of $0 for the first dose, and then $25 for each dose thereafter, with a maximum benefit of $10,000 per patient per calendar year.

Amgen Safety Net Foundation

Patients with limited or no drug coverage, and patients with Medicare Part D who satisfy the income eligibility requirements, can receive Xgeva for free through this nonprofit program from Amgen.

Cancer Pain

Actiq (fentanyl citrate)

Drug company: Teva
888-587-3263

Actiq is an opioid agonist used for the treatment of breakthrough pain in patients with cancer.

(Teva does not currently offer any direct financial assistance programs for Actiq.)

Fentora (fentanyl buccal tablet)

Drug company: Teva
888-587-3263

Fentora is used for the treatment of breakthrough pain in patients with cancer.

Teva offers 2 financial assistance programs for patients using Fentora:

Fentora Savings Card

Privately insured patients who are enrolled in the TIRF REMS Access Program (www.tirfremsaccess.com) are eligible to use this savings card. With the Fentora Savings Card, the first month of Fentora is free, and subsequent months require a $5 copay.

Teva Cares Foundation Patient Assistance Program

Patients without prescription drug coverage who meet specific financial criteria may receive Fentora for free. The financial criteria specify that the patient’s annual income must not exceed $36,420 for 1 person, $49,380 for 2 people, $62,340 for 3 people, $75,300 for 4 people, or $88,260 for 5 people.

Lazanda (fentanyl)

Drug company: Depomed
877-546-5779

Lazanda is an opioid agonist used for the treatment of breakthrough pain in patients with cancer.

Depomed offers 1 financial assistance program for patients using Lazanda:

Lazanda Savings Card

Patients with private insurance are eligible for this prescription savings card. With the card, eligible patients will pay a copay of $25 for a prescription of Lazanda, with a maximum benefit of up to $1,000, and a maximum of 30 bottles per 30 days.

Subsys (fentanyl sublingual spray)

Drug company: Insys
855-766-6502

Subsys is an opioid agonist used for the treatment of breakthrough pain in patients with cancer.

Insys offers 1 financial assistance program for patients using Subsys:

Subsys Copay Savings Program

Privately insured and uninsured patients can use this copay savings card to receive 10 free units of 100-mcg Subsys and/or up to 30 free units of 100 mcg to 1,600 mcg of Subsys. Patients will also receive up to $1,000 off each additional prescription of Subsys.

Chemotherapy-Induced Nausea and Vomiting

Akynzeo (netupitant and palonosetron)

Drug company: Helsinn
844-357-4668

Akynzeo is a fixed combination of netupitant and palonosetron used, in combination with dexamethasone, for the prevention of acute and delayed nausea and vomiting associated with cancer chemotherapy.

Helsinn Cares offers 3 financial assistance programs for patients using Akynzeo:

Akynzeo Capsule Savings Card

Privately insured patients will benefit from this program. Helsinn will pay up to $50 copay savings per Akynzeo capsule prescription.

Akynzeo Quick Start Voucher Program

This program is for patients whose insurance company requires prior authorization for Akynzeo. To be assessed for eligibility for the Akynzeo Quick Start Voucher Program, patients must be enrolled in Helsinn Cares. The program is available for all eligible patients with commercial or government-sponsored insurance plans. Through the Akynzeo Quick Start Voucher Program, patients will receive 1 free dose of Akynzeo during the insurance verification period.

Helsinn Cares Patient Assistance Program

This program provides Akynzeo at no cost to patients with financial needs who meet the program’s eligibility criteria.

Aloxi (palonosetron HCl) Injection

Drug company: Helsinn
844-357-4668

Aloxi is a serotonin-3 receptor antagonist used to prevent acute and delayed nausea and vomiting associated with cancer chemotherapy in pediatric and adult patients.

(Helsinn does not currently offer any direct financial assistance programs for Aloxi.)

Aloxi Patient Assistance Program

This program provides Aloxi at no cost to patients with financial needs who meet the program’s eligibility criteria.

Cesamet (nabilone)

Drug company: Meda Pharmaceuticals
800-526-3840

Cesamet is used for the treatment of patients with nausea and vomiting associated with cancer chemotherapy.

(Meda Pharmaceuticals does not currently offer any financial assistance program for Cesamet.)

Emend (aprepitant)

Drug company: Merck
855-257-3932

Emend is a substance P/neurokinin-1 receptor antagonist used to prevent nausea and vomiting associated with chemotherapy in pediatric and adult patients with cancer. Emend is also used to prevent postoperative nausea and vomiting in adults.

The Merck Access Program offers 1 financial assistance program for patients using Emend:

Merck Patient Assistance Program

Patients without insurance or prescription Patients without insurance or prescription coverage may be eligible to receive Emend free. Eligible patients must have an annual household income of $48,560 or less for individuals, $65,840 or less for couples, or $100,400 or less for a family of 4. Patients with insurance, including Medicare Part D, who still have difficulty paying for medicines may request that an exception be made, provided their annual household income is not more than a set limit.

Marinol (dronabinol)

Drug company: AbbVie
800-222-6885

Marinol is used for the treatment of patients with nausea and vomiting associated with cancer chemotherapy.

(AbbVie does not currently offer any financial assistance programs for Marinol.)

Sancuso (granisetron transdermal system)

Drug company: Kyowa Kirin
800-676-5884

Sancuso is a serotonin-3 receptor antagonist used to prevent nausea and vomiting in patients receiving chemotherapy for up to 5 consecutive days.

Kyowa Kirin offers 2 financial assistance programs for patients using Sancuso:

Sancuso Copay Assistance Card Program

Insured patients can use the Sancuso Copay Assistance Card for up to 48 patches per patient, with a maximum of 4 patches and $1,200 benefit monthly. With the card, patients will pay the initial $20 of their copay and any remaining out-of-pocket costs will be reduced by up to $300 monthly.

Sancuso Patient Assistance Program

Patients who do not have insurance and who do have an income at or below 300% of the current federal poverty level are eligible to receive free Sancuso.

Sustol (granisetron)

Drug company: Heron Therapeutics
855-787-8656

Sustol is a serotonin-3 receptor antagonist used, in combination with antiemetic agents, to prevent acute and delayed nausea and vomiting associated with chemotherapy.

Sustol Connect Patient Services offers 2 financial assistance programs for patients using Sustol:

Sustol Copay Assistance Program

Privately insured and uninsured patients can benefit from this copay program. Patients with private insurance will pay $0 copay per dose for a 12-month calendar period for Sustol. For uninsured patients, the program will cover $150 per prescription up to $1,800 per calendar year. Patients must reapply after each 12-month period.

Sustol Patient Assistance Program

Sustol can be provided at no cost to patients with financial hardship who meet the program eligibility criteria.

Varubi (rolapitant)

Drug company: TerSera
855-686-8725

Varubi is a substance P/neurokinin-1 receptor antagonist used, in combination with other antiemetic drugs, to prevent delayed nausea and vomiting in patients with cancer who are receiving chemotherapy.

TerSera Support Source offers 2 financial assistance programs for patients who have been prescribed Varubi:

Varubi Co-Pay Card

Eligible patients who have private insurance may pay as little as $0 for their prescription of Varubi, with a maximum benefit of $2,000 per year.

Varubi Patient Assistance Program

For eligible patients who do not have commercial insurance, this program will provide assistance with the cost of Varubi.

Cytokine Release Syndrome

Actemra (tocilizumab)

Drug company: Genentech
866-422-2377

Actemra is an interleukin-6 receptor antagonist used for the treatment of adults and pediatric patients age 2 or older who have CAR T-cell–induced, severe or life-threatening cytokine release syndrome.

Genentech offers 2 financial assistance programs for patients using Actemra:

Actemra Co-pay Card Program

This program helps eligible, privately insured patients, who have been prescribed Actemra for any approved indication, to pay just $5 per drug copay. The card is valid for up to $15,000 in assistance within a 12-month period.

Genentech Patient Foundation

This foundation provides Actemra free of charge to uninsured or underinsured patients whose annual household income is less than $150,000. Actemra is also provided free of charge for patients whose annual household income is up to $75,000 for 1 person; $100,000 for 2 people; $125,000 for 3 people; $150,000 for 4 people; and up to $25,000 more for each additional person in the household.

Neutropenia/Febrile Neutropenia

Fulphila (pegfilgrastim-jmdb)

Drug company: Mylan
833-695-2623

Fulphila, a biosimilar to Neulasta, is a leukocyte growth factor used to reduce the risk of infection associated with febrile neutropenia in patients with non-myeloid cancer who are receiving myelosuppressive chemotherapy.

Mylan Advocate offers 1 financial assistance program for patients who have been prescribed Fulphila:

Mylan Advocate Co-Pay Assistance Program

For patients who have private insurance and meet eligibility criteria, this program will pay the full amount of the patient’s out-of-pocket cost of Fulphila, with a maximum benefit of $10,000 per 12

Neulasta (pegfilgrastim)

Drug company: Amgen
888-427-7478

Neulasta is a leukocyte growth factor used to decrease the incidence of infection associated with febrile neutropenia in patients with non-myeloid cancer who are receiving myelosuppressive chemotherapy.

Amgen offers 2 financial assistance programs for patients using Neulasta:

Neulasta FIRST STEP Program

For privately insured patients whose insurance covers Neulasta, this program ensures a copay of $0 for the first dose, and $25 for each dose thereafter, with a maximum benefit of $10,000 per patient per calendar year.

Amgen Safety Net Foundation

Patients with limited or no drug coverage, and patients with Medicare Part D who satisfy the income eligibility requirements, can receive Neulasta for free through this nonprofit program from Amgen.

Neupogen (filgrastim)

Drug company: Amgen
888-427-7478

Neupogen is a leukocyte growth factor used to decrease infections associated with febrile neutropenia in patients with non-myeloid cancer who are receiving myelosuppressive chemotherapy. Neupogen is also used for the treatment of patients with neutropenia in patients with cancer.

Amgen offers 2 financial assistance programs for patients using Neupogen:

Neupogen FIRST STEP Program

For privately insured patients whose insurance covers Neupogen, this program ensures a copay of $0 for the first dose, and $25 for each dose thereafter, with a maximum benefit of $10,000 per patient per calendar year.

Amgen Safety Net Foundation

Patients with limited or no drug coverage, and patients with Medicare Part D who satisfy the income eligibility requirements, can receive Neupogen for free through this nonprofit program from Amgen.

Udenyca (pegfilgrastim-cbqv)

Drug company: Coherus BioSciences
844-483-3692

Udenyca, a biosimilar to Neulasta, is a leukocyte growth factor used to decrease the risk of infection associated with febrile neutropenia in patients with non-myeloid cancer who are receiving myelosuppressive chemotherapy.

Coherus COMPLETE offers 2 financial assistance programs for patients who have been prescribed Udenyca:

Coherus COMPLETE Co-Pay Assistance Program

This program reduces the patient’s out-of-pocket costs of Udenyca for patients who have commercial insurance. The out-of-pocket cost for eligible patients is $0 per dose of Udenyca, with a maximum benefit of up to $7,200 per claim, and a maximum annual benefit of $15,000 per 12-month enrollment period.

Coherus COMPLETE Patient Assistance Program

Patients who are uninsured or underinsured and have financial hardship may receive Udenyca at no cost for 1 year through this program.

Zarxio (filgrastim-sndz)

Drug company: Sandoz
844-726-3691

Zarxio, a biosimilar to Neupogen, is a leukocyte growth factor used to decrease the risk of infection associated with febrile neutropenia in patients with cancer. Zarxio is also used for the treatment of neutropenia in patients with cancer.

Sandoz One Source Commercial Co-Pay Program

Through this program, privately insured patients will pay $0 for the first dose of Zarxio and $10 for subsequent doses with a maximum benefit of $10,000 annually. There is no income eligibility requirement.

Table. Drugs Prescribed for Side-Effects Management (Supportive Care)

Anemia
  • Drug name (generic name)
  • Drug company
  • Indication
  • Patient support services
    Drug name (generic name)
  • Aranesp (darbepoetin alfa)
  • Drug company
  • Amgen
  • Indication
  • Anemia
  • Patient support services
  • Amgen Safety Net Foundation
    888-762-6436

    Drug name (generic name)
  • Epogen (epoetin alfa)
  • Drug company
  • Amgen
  • Indication
  • Anemia
  • Patient support services
  • (No specific program)
    888-427-7478


    Drug name (generic name)
  • Retacrit (epoetin alfa-epbx)
  • Drug company
  • Pfizer
  • Indication
  • Treatment of anemia associated with myelosuppressive chemotherapy
  • Patient support services
  • Pfizer Patient Assistance Program
    844-722-6672

Bone Metastases/Reduced Bone Mass
  • Drug name (generic name)
  • Drug company
  • Indication
  • Patient support services
    Drug name (generic name)
  • Prolia (denosumab) Injection
  • Drug company
  • Amgen
  • Indication
  • To increase bone mass in high-risk men receiving androgen-deprivation therapy for nonmetastatic prostate cancer, and in women receiving adjuvant aromatase inhibitor therapy for breast cancer
  • Patient support services
  • Prolia Copay Program
    844-369-9962

    Prolia FIRST STEP Program
    888-657-8371

    Amgen Safety Net Foundation
    888-762-6436


Cancer Pain
  • Drug name (generic name)
  • Drug company
  • Indication
  • Patient support services
    Drug name (generic name)
  • Actiq (fentanyl citrate)
  • Drug company
  • Teva
  • Indication
  • Breakthrough cancer pain
  • Patient support services
  • (No specific program)
    888-587-3263


    Drug name (generic name)
  • Lazanda (fentanyl)
  • Drug company
  • Depomed
  • Indication
  • Breakthrough cancer pain
  • Patient support services
  • Lazanda Savings Card
    877-546-5779

    Drug name (generic name)
  • Subsys (fentanyl sublingual spray)
  • Drug company
  • Insys
  • Indication
  • Breakthrough cancer pain
  • Patient support services
  • Subsys Copay Savings Program
    855-766-6502

Chemotherapy-Induced Nausea and Vomiting
  • Drug name (generic name)
  • Drug company
  • Indication
  • Patient support services

    Drug name (generic name)
  • Aloxi (palonosetron hydrochloride)
  • Drug company
  • Helsinn
  • Indication
  • Chemotherapy-induced nausea and vomiting
  • Patient support services
  • (No specific program)
    844-357-4668

    Drug name (generic name)
  • Cesamet (nabilone)
  • Drug company
  • Meda Pharmaceuticals
  • Indication
  • Chemotherapy-induced nausea and vomiting
  • Patient support services
  • (No specific program)
    800-526-3840

    Drug name (generic name)
  • Emend (aprepitant)
  • Drug company
  • Merck
  • Indication
  • Chemotherapy-induced nausea and vomiting

    Postoperative nausea and vomiting
  • Patient support services
  • Merck Patient Assistance Program
    855-257-3932

    Drug name (generic name)
  • Marinol (dronabinol)
  • Drug company
  • AbbVie
  • Indication
  • Chemotherapy-induced nausea and vomiting
  • Patient support services
  • (No specific program)
    800-222-6885



    Drug name (generic name)
  • Varubi (rolapitant)
  • Drug company
  • TerSera
  • Indication
  • Prevent chemotherapy-induced nausea and vomiting, in
    combination with other antiemetic drugs
  • Patient support services
  • Varubi Co-Pay Card
    866-255-8702

    Varubi Patient Assistance Program
    855-686-8725


Cytokine Release Syndrome
  • Drug name (generic name)
  • Drug company
  • Indication
  • Patient support services

Neutropenia/Febrile Neutropenia
  • Drug name (generic name)
  • Drug company
  • Indication
  • Patient support services
    Drug name (generic name)
  • Fulphila (pegfilgrastim-jmdb)
  • Drug company
  • Mylan
  • Indication
  • Treatment of febrile neutropenia associated with myelosuppressive chemotherapy
  • Patient support services
  • Mylan Advocate Co-Pay Assistance Program
    833-695-2623






Last modified: February 11, 2019

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.

Country